TNFSF10, TNF superfamily member 10, 8743

N. diseases: 445; N. variants: 10
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023418
Disease: leukemia
leukemia 		0.400 Biomarker disease BEFREE These data suggest that TRAIL might participate in CD95-independent apoptosis of lymphoid cells and might be involved in deregulated apoptosis in diseases such as leukemias and HIV-1 infection. 9485194 1998
CUI: C2363741
Disease: HIV-1 infection
HIV-1 infection 		0.060 Biomarker disease BEFREE These data suggest that TRAIL might participate in CD95-independent apoptosis of lymphoid cells and might be involved in deregulated apoptosis in diseases such as leukemias and HIV-1 infection. 9485194 1998
CUI: C0017638
Disease: Glioma
Glioma 		0.400 AlteredExpression disease BEFREE We analyzed the expression of TRAIL and its receptors in a panel of human brain tumors (n = 34) and in four glioma cell lines in comparison to normal brain tissue. 10198234 1999
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.400 Biomarker disease BEFREE Enhanced levels of ceramide may be involved in apoptosis signaling following stroke since exogenously added synthetic C2-ceramide increased expression of c-jun and the death-inducing ligands (DILs) CD95-L, TRAIL and TNF-alpha in neuroblastoma cells. 10224298 1999
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.100 Biomarker disease BEFREE Furthermore, we provide first time evidence that similar to Fas, TRAIL-induced apoptosis is not blocked by bcl-2 in MM cell lines. 10557057 1999
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 Biomarker disease BEFREE Enhanced levels of ceramide may be involved in apoptosis signaling following stroke since exogenously added synthetic C2-ceramide increased expression of c-jun and the death-inducing ligands (DILs) CD95-L, TRAIL and TNF-alpha in neuroblastoma cells. 10224298 1999
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 Biomarker disease BEFREE Enhanced levels of ceramide may be involved in apoptosis signaling following stroke since exogenously added synthetic C2-ceramide increased expression of c-jun and the death-inducing ligands (DILs) CD95-L, TRAIL and TNF-alpha in neuroblastoma cells. 10224298 1999
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms 		0.040 AlteredExpression group BEFREE We analyzed the expression of TRAIL and its receptors in a panel of human brain tumors (n = 34) and in four glioma cell lines in comparison to normal brain tissue. 10198234 1999
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident 		0.030 AlteredExpression group BEFREE Enhanced levels of ceramide may be involved in apoptosis signaling following stroke since exogenously added synthetic C2-ceramide increased expression of c-jun and the death-inducing ligands (DILs) CD95-L, TRAIL and TNF-alpha in neuroblastoma cells. 10224298 1999
CUI: C0001175
Disease: Acquired Immunodeficiency Syndrome
Acquired Immunodeficiency Syndrome 		0.010 Biomarker group BEFREE These findings suggest the possible involvement of Bcl-xL in Act D-induced sensitization of AIDS-KS cells to Apo-2L-mediated apoptosis. 10228045 1999
CUI: C0036220
Disease: Kaposi Sarcoma
Kaposi Sarcoma 		0.010 Biomarker disease BEFREE Apo-2L induced apoptosis in >80% of AIDS-KS cells pretreated with Act D. The caspase inhibitors, zIETD-fmk and zDEVD-fmk, inhibited apoptosis in AIDS-KS by sApo-2L, suggesting that caspase 3-like and caspase 8 or 10 activities are essential for Apo-2L-mediated apoptosis. 10228045 1999
CUI: C0276535
Disease: AIDS with Kaposi's sarcoma
AIDS with Kaposi's sarcoma 		0.010 Biomarker disease BEFREE Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D. 10228045 1999
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon 		0.400 AlteredExpression disease BEFREE Subsequent overexpression of TRUNDD in colon cancer cell lines caused a significant delay in killing induced by TRAIL. 10933923 2000
CUI: C0007134
Disease: Renal Cell Carcinoma
Renal Cell Carcinoma 		0.400 Biomarker disease BEFREE This synergistic effect of cotreatment with Topotecan and TRAIL may provide the basis for a new therapeutic approach to induce apoptosis in otherwise unresponsive RCC. 11139287 2000
CUI: C0555198
Disease: Malignant Glioma
Malignant Glioma 		0.400 Biomarker disease BEFREE TNF-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in adult malignant glioma and various other human solid tumor models but not in normal tissues. 11030149 2000
CUI: C0279702
Disease: Conventional (Clear Cell) Renal Cell Carcinoma
Conventional (Clear Cell) Renal Cell Carcinoma 		0.380 Biomarker disease BEFREE This synergistic effect of cotreatment with Topotecan and TRAIL may provide the basis for a new therapeutic approach to induce apoptosis in otherwise unresponsive RCC. 11139287 2000
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE TRAIL appears to be a cancer-specific cytotoxic agent and thus offers promise as a novel therapy for cancer either through replacement of the cytokine or potentially via gene replacement. 10810622 2000
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE These results define a novel method of using TRAIL as an antitumor therapeutic, and suggest the potential use for an adenovirus-encoding TRAIL as a method of gene therapy for numerous cancer types in vivo. 10946322 2000
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE Activation of caspase-9 also appeared necessary for TRAIL-induced apoptosis of melanoma. 11067917 2000
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE Infection of A2058-E1A cells with Ad5 reduced their sensitivity to TRAIL-dependent killing. 11035092 2000
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE These results indicate that abnormalities in "decoy" receptor location or function may contribute to sensitivity of melanoma to TRAIL-induced apoptosis and suggest that further studies are needed on the functional significance of their nuclear location and TRAIL-induced movement within cells. 10754286 2000
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE While further evaluation of the role of TRAIL receptors in human cancer is ongoing, initial studies suggest that both KILLER/DR5 and DR4 may be targets for inactivation and that these pro-apooptotic receptors may be tumor suppressor genes. 10810622 2000
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE In vivo effects of TRAIL on tumor growth were investigated after subcutaneous injection of cholangiocarcinoma cells into nude mice. 10960444 2000
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE The results presented in this study demonstrate that introduction of the human TRAIL gene into TRAIL-sensitive tumor cells using an adenoviral vector leads to the rapid production and expression of TRAIL protein, and subsequent death of the tumor cells. 10946322 2000
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.100 AlteredExpression disease BEFREE Subsequent overexpression of TRUNDD in colon cancer cell lines caused a significant delay in killing induced by TRAIL. 10933923 2000